https://www.live-feeds.com/feed/astrazeneca-ends-phase-3-lung-cancer-drug-trial-after-reviewContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/astrazeneca-ends-phase-3-lung-cancer-drug-trial-after-reviewhttps://www.live-feeds.com/feed/astrazeneca-ends-phase-3-lung-cancer-drug-trial-after-review#u44769Tue, 18 Aug 2026 06:05:36 +0000AstraZeneca has ended a Phase 3 trial of its lung cancer drug volrustomig, citing low likelihood of success. The trial, known as eVOLVE-Lung02, was testing volrustomig in combination with chemotherapy for metastatic non-small cell lung cancer. The decision to stop the trial was made after a review. AstraZeneca has suffered another setback in its lung cancer pipeline.Why it mattersThe trial's failure is a blow to AstraZeneca's lung cancer treatment efforts. Lung cancer is a leading cause of cancer deaths worldwide, and effective treatments are in high demand. The company's decisi